Dilated Cardiomyopathy Market Size in the 7MM Reached USD 463.6 million in 2023 and It is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Dilated Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dilated Cardiomyopathy, historical and forecasted epidemiology as well as the Dilated Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To know in detail about the Dilated Cardiomyopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here @ Dilated Cardiomyopathy Market Forecast- https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key facts of the Dilated Cardiomyopathy Market Report
• In the 7MM, the total dilated cardiomyopathy prevalence were estimated to be approximately 3,045,174 in 2023, of which the US accounted for around 45%, while EU4 and the UK accounted for nearly 43%, and Japan accounted for approximately 12% of the total dilated cardiomyopathy prevalent cases. These cases are expected to increase by 2034.
• Among the 7MM, the US accounted for nearly 52% of the total diagnosed dilated cardiomyopathy prevalence. These cases are expected to increase during the study period (2020-2034).
• As per DelveInsight analysis, EU4 and the UK accounted for around 402,538 diagnosed prevalent cases of dilated cardiomyopathy in 2023. These cases are expected to change during the forecast period (2024-2034).
• Among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of dilated cardiomyopathy, accounting for nearly 103,096 cases, followed by France and the UK with approximately 83,529, and 83,410, respectively while Spain had the least cases i.e. around 57,806 in 2023.
• According to estimates based on DelveInsight's epidemiology model, dilated cardiomyopathy exhibits a higher male preponderance than females in the US. Of the total diagnosed prevalent cases in the US, nearly 63% were males and 37% were females, in 2023.
• In the US, there were nearly 194,036 cases due to family history or genetic causes, while other non-familial causes accounted for approximately 360,352 cases in 2023. As per the analysis, these cases are expected to increase by 2034.
• In 2023, among the 7MM, Japan had the second-highest cases of dilated cardiomyopathy, contributing approximately 11% to the total diagnosed prevalent cases of dilated cardiomyopathy.
• As per DelveInsight's estimates, in Japan, non-familial/other cases and genetic/familial cases of dilated cardiomyopathy accounted for 70% and 30% of the total diagnosed cases of dilated cardiomyopathy respectively in 2023, which are expected to increase by 2034.
• The Dilated Cardiomyopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dilated Cardiomyopathy pipeline products will significantly revolutionize the Dilated Cardiomyopathy market dynamics.
• The Dilated Cardiomyopathy market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• The leading Dilated Cardiomyopathy Companies such as Pfizer, Capricor Therapeutics, MyoKardia, Cumberland Pharmaceuticals, Berlin Cures, Vericel, and others
• Promising Dilated Cardiomyopathy Therapies such as Danicamtiv, Ixmyelocel, ARRY-371797, Ifetroban, BC 007, and others.

Stay ahead in the Dilated Cardiomyopathy Therapeutics Market with DelveInsight's Strategic Report @ Dilated Cardiomyopathy Market Outlook- https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dilated Cardiomyopathy Overview
Dilated Cardiomyopathy (DCM) is a heart condition characterized by the enlargement and dilation of one or both ventricles, along with impaired contractility indicated by a left ventricular ejection fraction (LVEF) below 40%. DCM typically progresses, often leading to heart failure and high mortality rates without transplantation. There are various causes of DCM, each affecting ventricular function to different degrees. While many patients with DCM experience symptoms, some may be asymptomatic initially due to compensatory mechanisms. However, ongoing ventricular enlargement eventually compromises heart function, leading to issues such as irregularities in the conduction system, ventricular arrhythmias, thromboembolism, and ultimately heart failure. Early identification and treatment of these patients are crucial for improving outcomes and prognosis.

Dilated Cardiomyopathy Epidemiology Segmentation in the 7MM
• Total Prevalence of Dilated Cardiomyopathy
• Prevalent Cases of Dilated Cardiomyopathy by severity
• Gender-specific Prevalence of Dilated Cardiomyopathy
• Diagnosed Cases of Episodic and Chronic Dilated Cardiomyopathy

Download the report to understand which factors are driving Dilated Cardiomyopathy epidemiology trends @ Dilated Cardiomyopathy Epidemiology Forecast- https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dilated Cardiomyopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dilated Cardiomyopathy market or expected to get launched during the study period. The analysis covers Dilated Cardiomyopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Dilated Cardiomyopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dilated Cardiomyopathy Therapies
• Danicamtiv
• Ixmyelocel
• ARRY-371797
• Ifetroban
• BC 007

Dilated Cardiomyopathy Companies
• Pfizer
• Capricor Therapeutics
• MyoKardia
• Cumberland Pharmaceuticals
• Berlin Cures
• Vericel

Request for a sample report @ https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Dilated Cardiomyopathy Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Key Dilated Cardiomyopathy Companies: Pfizer, Capricor Therapeutics, MyoKardia, Cumberland Pharmaceuticals, Berlin Cures, Vericel, and others
• Key Dilated Cardiomyopathy Therapies: Danicamtiv, Ixmyelocel, ARRY-371797, Ifetroban, BC 007, and others
• Dilated Cardiomyopathy Therapeutic Assessment: Dilated Cardiomyopathy current marketed and Dilated Cardiomyopathy emerging therapies
• Dilated Cardiomyopathy Market Dynamics: Dilated Cardiomyopathy market drivers and Dilated Cardiomyopathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dilated Cardiomyopathy Unmet Needs, KOL's views, Analyst's views, Dilated Cardiomyopathy Market Access and Reimbursement

To know more about Dilated Cardiomyopathy companies working in the treatment market, visit @ Dilated Cardiomyopathy Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Dilated Cardiomyopathy Market Report Introduction
2. Executive Summary for Dilated Cardiomyopathy
3. SWOT analysis of Dilated Cardiomyopathy
4. Dilated Cardiomyopathy Patient Share (%) Overview at a Glance
5. Dilated Cardiomyopathy Market Overview at a Glance
6. Dilated Cardiomyopathy Disease Background and Overview
7. Dilated Cardiomyopathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Dilated Cardiomyopathy
9. Dilated Cardiomyopathy Current Treatment and Medical Practices
10. Dilated Cardiomyopathy Unmet Needs
11. Dilated Cardiomyopathy Emerging Therapies
12. Dilated Cardiomyopathy Market Outlook
13. Country-Wise Dilated Cardiomyopathy Market Analysis (2020-2034)
14. Dilated Cardiomyopathy Market Access and Reimbursement of Therapies
15. Dilated Cardiomyopathy Market Drivers
16. Dilated Cardiomyopathy Market Barriers
17. Dilated Cardiomyopathy Appendix
18. Dilated Cardiomyopathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.